We are stepping up and buying Albemarle (ALB US) into protracted weakness. This aligns with our more positive view of the Lithium market.
We are cutting our position in Glencore (GLEN LN) after the stock broke key support. We think the next 12 months will be a complex one from a corporate perspective, and prefer to tweak our exposure towards Lithium via Albemarle (ALB US).
We are adding to our existing position in UBS Group (UBS US) following last week’s result. We currently hold a 3% weighting, increasing this by a further 2%, targetting a 5% portfolio weighting.